Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.63
- Piotroski Score 2.00
- Grade Overweight
- Symbol (MESO)
- Company Mesoblast Limited
- Price $10.77
- Changes Percentage (12.77%)
- Change $1.22
- Day Low $9.91
- Day High $11.05
- Year High $11.05
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/26/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.50
- High Stock Price Target $12.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.82
- Trailing P/E Ratio -8.71
- Forward P/E Ratio -8.71
- P/E Growth -8.71
- Net Income $-87,956,000
Income Statement
Quarterly
Annual
Latest News of MESO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
For Fredric Jameson, Marxist Criticism Was a Labor of Love
Fredric Jameson, a prominent Marxist literary critic, passed away at 90, emphasizing the importance of reading for revolution. He was known for his deep analysis of literature within social structures...
By The New York Times | 1 week ago -
Best Mesothelioma Lawyers San Antonio, TX Of 2024
Mesothelioma is a deadly disease with a low survival rate. Laws and regulations by the EPA, OSHA, and Texas DSHS are in place to monitor and restrict asbestos use, protect workers, and prevent exposur...
By Forbes | 1 week ago -
Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies
Mesoblast (NASDAQ:MESO) is a biotech company in Melbourne focusing on regenerative medicine. It's developing rexlemestrocel-L and remestemcel-L, with FDA approvals pending. With 3 hedge fund investors...
By Yahoo! Finance | 2 weeks ago
